Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.56 |
| ▸ | BLM | P54132 | 2/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.56 |
| ▸ | HTR2A | P28223 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.56 |
| ▸ | HTR7 | P34969 | 1/20 | 0.56 |
| ▸ | HTR2B | P41595 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1572564 | 1.00 | KDM4E (0.56) | KDM4EALOX15HSD17B10LMNAALDH1A1 | |
| SCHEMBL31189933 | 1.00 | KDM4E (0.56) | KDM4EALOX15HSD17B10LMNAALDH1A1 | |
| SCHEMBL29286183 | 0.86 | USP2 (0.50) | KDM4EALOX15HSD17B10LMNAALDH1A1 | |
| SCHEMBL29286185 | 0.86 | USP2 (0.50) | KDM4EALOX15HSD17B10LMNAALDH1A1 | |
| SCHEMBL10938099 | 0.85 | KMT2A (0.61) | KDM4EALOX15HSD17B10LMNAALDH1A1 | |
| SCHEMBL4355962 | 0.85 | KMT2A (0.61) | KDM4EALOX15HSD17B10LMNAALDH1A1 | |
| SCHEMBL836727 | 0.85 | KMT2A (0.61) | KDM4EALOX15HSD17B10LMNAALDH1A1 | |
| SCHEMBL2679928 | 0.84 | KDM4E (0.66) | KDM4EALOX15HSD17B10LMNAALDH1A1 | |
| SCHEMBL4140820 | 0.84 | KDM4E (0.66) | KDM4EALOX15HSD17B10LMNAALDH1A1 | |
| SCHEMBL569807 | 0.84 | SLC7A5 (0.58) | KDM4EALOX15HSD17B10LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 458 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747409-A2 | COLLECTION, ASSESSMENT AND EARLY DETECTION OF HUMAN LUNG CANCER BIOMARKERS IN EXHALED BREATH CONDENSATES OF MOUSE ANIMAL MODELS | Hackensack Meridian Health, Inc. (US) | 2026-05-27 | — | — | EP | claimed |
| US-12345655-B1 | Subsurface defect detecting device for cylindrical components and method thereof | TAIYUAN UNIVERSITY OF TECHNOLOGY (CN) | 2025-07-01 | — | — | US | claimed |
| CN-115097144-B | B-type natriuretic peptide detection kit and preparation method thereof | 四川新健康成生物股份有限公司 | 2025-05-20 | — | — | CN | claimed |
| CN-119868594-A | Method for radiolabelling GRPR antagonist and kit thereof | 诺华股份有限公司 | 2025-04-25 | — | — | CN | claimed |
| WO-2025019709-A2 | COLLECTION, ASSESSMENT AND EARLY DETECTION OF HUMAN LUNG CANCER BIOMARKERS IN EXHALED BREATH CONDENSATES OF MOUSE ANIMAL MODELS | HACKENSACK MERIDIAN HEALTH, INC. (US) | 2025-01-23 | — | — | WO | claimed |
| CN-119335197-A | Kit for auxiliary diagnosis of Alzheimer's disease as well as preparation method and application thereof | 四川新健康成生物股份有限公司 | 2025-01-21 | — | — | CN | claimed |
| CN-119335177-A | Preparation method of alkaline phosphatase labeled CTNI antibody | 桂林优利特医疗电子有限公司 | 2025-01-21 | — | — | CN | claimed |
| CN-114755410-B | Alkaline phosphatase-labeled antibody reagent | 三诺生物传感股份有限公司 | 2024-12-31 | — | — | CN | claimed |
| US-20240410022-A1 | COLLECTION, ASSESSMENT AND EARLY DETECTION OF HUMAN LUNG CANCER BIOMARKERS IN EXHALED BREATH CONDENSATES OF MOUSE ANIMAL MODELS | HACKENSACK MERIDIAN HEALTH, INC. (US) | 2024-12-12 | — | — | US | claimed |
| CN-116471435-B | Voice and caption adjusting method and device, electronic equipment and storage medium | 央视国际网络有限公司 | 2024-11-29 | — | — | CN | claimed |
| US-11053249-B2 | Proteasome inhibiting β-lactam prodrugs useful for the treatment of cancer and neurodegenerative disorders | PHILIPPE YVES-REMY SIMON (FR) | 2021-07-06 | — | — | US | claimed |
| US-20200216455-A1 | Proteasome Inhibiting Beta-Lactam Produrgs Useful for the Treatment of Cancer and Nurodegenerative Disorders | VITA API (FR) | 2020-07-09 | — | — | US | claimed |
| WO-2018115497-A1 | PROTEASOME INHIBITING ß-LACTAM PRODRUGS USEFUL FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISORDERS | VITA API (FR) | 2018-06-28 | — | — | WO | claimed |
| EP-3339291-A1 | PROTEASOME INHIBITING SS-LACTAM PRODRUGS USEFUL FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISORDERS | VITA API (FR) | 2018-06-27 | — | — | EP | claimed |
| CN-102319255-B | Anti-radiation spriulina polysaccharide organic bio-active iodine and application thereof | ZHAO BO | 2013-03-27 | — | — | CN | claimed |
| CN-102319255-A | Anti-radiation spriulina polysaccharide organic bio-active iodine and application thereof | BO ZHAO | 2012-01-18 | — | — | CN | claimed |
| US-7399619-B2 | Site specific incorporation of heavy atom-containing unnatural amino acids into proteins for structure determination | THE SCRIPPS RESEARCH INSTITUTE (US) | 2008-07-15 | — | — | US | claimed |
| US-20050272121-A1 | Translation system including an orthogonal aminoacyl-transfer RNA synthetase with a specific sequence that preferentially aminoacylates an orthogonal transfer RNA with a brominated or iodinated phenylalanine or tyrosine | THE SCRIPPS RESEARCH INSTITUTE (US) | 2005-12-08 | — | — | US | claimed |
| CN-1217658-C | Organic bio-iodine and its use | ZHAO BO (CN) | 2005-09-07 | — | — | CN | claimed |
| CN-1528279-A | Organic bio-iodine and its use | 赵 波 | 2004-09-15 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272121-A1 | Translation system including an orthogonal aminoacyl-transfer RNA synthetase with a specific sequence that preferentially aminoacylates an orthogonal transfer RNA with a brominated or iodinated phenylalanine or tyrosine | AARS1, NSUN3, TARBP1 | KDM4E 2732/4885ALOX15 4436/4885HSD17B10 2224/4885 |
| US-11053249-B2 | Proteasome inhibiting β-lactam prodrugs useful for the treatment of cancer and neurodegenerative disorders | PSMB5, PSMB1, PSMB11 | KDM4E 1063/4885ALOX15 2434/4885HSD17B10 1893/4885 |
| US-20200216455-A1 | Proteasome Inhibiting Beta-Lactam Produrgs Useful for the Treatment of Cancer and Nurodegenerative Disorders | PSMB5, PSMB1, PSMB11 | KDM4E 1964/4885ALOX15 2878/4885HSD17B10 1810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.